The U.S. Food and Drug Administration issued its first formal guidance on how to design and run clinical trials for psychedelic drugs, a move that directly clears a path for psilocybin, the active ...

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

The results are a pivotal achievement for psychedelic medicines. More than 100m people worldwide struggle with depression that does not respond to conventional treatments, and psychedelics have long ...

TheFly reported on February 14 that LifeSci Capital was bullish on CMPS, as the firm initiated coverage on the stock with a ...

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

Comparing Compass Pathways PLC's Short Interest Against Its Peers. Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performi ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have ...

The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be $150.0 million. Compass ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.